A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Abstract Background Strategies to improve activity of immune checkpoint inhibitors for triple-negative breast cancer (TNBC) are needed. Preclinical studies showed that antiangiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors might sensitize tumors to immunotherapy. Here, we investiga...

Full description

Bibliographic Details
Main Authors: Qingyuan Zhang, Bin Shao, Zhongsheng Tong, Quchang Ouyang, Yuting Wang, Guoying Xu, Shaorong Li, Huiping Li
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Medicine
Subjects:
Camrelizumab
Apatinib
Fuzuloparib
TNBC
PARP
VEGFR
Online Access:https://doi.org/10.1186/s12916-022-02527-6

Internet

https://doi.org/10.1186/s12916-022-02527-6

Similar Items